Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
NCT05891379
·
clinicaltrials.gov ↗
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG:
Inebilizumab
DRUG:
oral immunosuppressant
Sponsor
Xuanwu Hospital, Beijing